Eikon Therapeutics, Inc. EIKN
5.87 USD -0.03 (-0.51%)
At closeNov 9, 2026, 4:00 PM EST
5.87 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
5.62 Day range 6.04
5.01 52-week range 17.40
- YTD
- -60.87%
- 1 year
- -60.87%
- Market cap
- 317.95M
- EPS (ttm)
- -8.51
- YTD return
- -60.87%
- 1-year return
- -60.87%
- Volume
- 722.19K
- Avg volume
- 575.06K
- Open
- 6.03
- Previous close
- 5.90
- Day's range
- 5.62 – 6.04
- 52-week range
- 5.01 – 17.40
5D +0.55 (+10.28%)
Financials — quick view
EIKN Revenue — quarterly 0
EIKN Net income — quarterly -88.41M
EIKN EPS — quarterly -1.63
News
Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029 
Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting 
Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile 
HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23 
Eikon Therapeutics Files Submits Investigational New Drug Application To FDA To Evaluate EIK1006 To Treat Advanced Metastatic Prostate Cancer
Your note
Sign in to keep a note on EIKN — it syncs with the Stock Master app.